MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

Written by Customer Service on June 22, 2022. Posted in Public Companies.

LA JOLLA, Calif., June 22, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration with Juntendo University, School of Medicine (2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan) to evaluate the mechanism of the action of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome. The lead collaborator is Takashi Mitsui MD, Ph.D., professor and the chair of the Department of Laboratory Medicine, a known leading expert on lipid metabolism who specializes in dyslipidemia and metabolic syndrome. Kazuko Matsuda, MD, Ph.D., MPH, Chief Medical Officer of MediciNova, Inc, commented, “MN 001 is a novel orally-administered compound with...

Texas Water Service Completes Purchase of Railyard Utility Wastewater System with Partner BVRT Utility Holding Company

Written by Customer Service on June 22, 2022. Posted in Public Companies.

SAN JOSE, Calif., June 22, 2022 (GLOBE NEWSWIRE) — California Water Service Group (NYSE:CWT) subsidiary Texas Water Service (Texas Water), through its strategic partnership with BVRT Utility Holding Company, has completed the acquisition of Railyard Utility’s wastewater system. This is the fifth utility owned and operated by Texas Water and BVRT. Railyard Utility, renamed Spanish Trail Utility, currently provides wastewater utility service to 345 customers near BVRT’s Plum Creek Utility and Windy Hill Utility systems in the Austin metropolitan area. An estimated additional 150 customers can be served when the community has been built out. “We are pleased to be growing our wastewater utility operations with BVRT in the great state of Texas and appreciate the trust placed in our team to serve former Railyard customers,” said Martin...

Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Written by Customer Service on June 22, 2022. Posted in Public Companies.

Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with solid tumors that have a BRAF V600E mutation1,2 Approval supported by results from Phase II ROAR and NCI-MATCH studies demonstrating overall response rates up to 80% in patients with BRAF V600E solid tumors1,2 BRAF mutations drive tumor growth across more than 20 tumor types, including thyroid, brain and gynecologic cancers3,4 Basel, June 23, 2022 — Novartis today announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation...

Alvotech Debuts on NASDAQ First North Growth Market Becoming First Dual-Listed Icelandic Company in United States and Iceland

Written by Customer Service on June 22, 2022. Posted in Public Companies.

After the largest debut by an Icelandic company on a U.S. stock exchange, Alvotech is set to list its shares under the ticker symbol “ALVO” on the Nasdaq First North Growth Market in Iceland commencing on June 23. Public listing on Nasdaq First North Growth in Iceland offers Icelandic investors exposure to a publicly traded, pure play, global company that has built an integrated platform for developing and producing biosimilars at scale. Financing facilities expected to be available to replace the value of redemptions from the completed business combination. REYKJAVIK, Iceland, June 22, 2022 (GLOBE NEWSWIRE) — Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced that its ordinary shares will be admitted to trading on the Nasdaq First...

Endexx to Launch Men’s Skincare Line in Amazon’s Store

Written by Customer Service on June 22, 2022. Posted in Public Companies.

Endexx Will Build on Continued Growth and Success of Its Men’s Skincare and Grooming Category to Expand and Deepen Connection With Consumers CAVE CREEK, AZ, June 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Endexx Corporation (OTCBB: EDXC) today received clearance for its Hemp-Derived and Plant-Based Skincare and grooming products in Amazon’s store. The products are rich in plant derived nutrients proven to support healthy skin. This product line has no Cannabidiol or THC in its formulation, providing a clear and compliant pathway to successful e-commerce in the Amazon Seller’s Central Platform. The line has been cleared to sell in the USA, Mexico and Canada, with pending approvals in Japan, United Kingdom and Australia. Initially, the rollout with up to six SKUs available to consumers. The store is being professionally...

Supplement to the Company Description

Written by Customer Service on June 22, 2022. Posted in Public Companies.

In connection to the filling on Form 20-F with the U.S. Securities and Exchange Commission (SEC), Alvotech has published a supplement dated 22 June 2022 to the Company Description, dated 21 June 2022. The Supplement will form part of and must be read and construed in conjunction with the Company Description dated 21 June 2022. The supplement is available for viewing on Alvotech‘s website : https://investors.alvotech.com/prospectus

Acasti Pharma Announces Annual Grants of Performance Stock Options

Written by Customer Service on June 22, 2022. Posted in Public Companies.

LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced the annual grant of performance stock options to its employees and executives. An aggregate of 1,212,500 stock options were granted to certain employees and executives of the Company under the Company’s stock option plan (“Stock Option Plan”). Subject to the terms and conditions of the Stock Option Plan, options granted to executives and employees will vest in equal quarterly installments over a period of 36 months. Each option will entitle the holder to purchase one common share of Acasti at a price of CDN$1.15, until June 22, 2032. The stock options were granted by...

Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

Written by Customer Service on June 22, 2022. Posted in Earnings Releases And Operating Results.

Management to host conference call at 8:00 AM Eastern Time on Thursday, June 23, 2022 TORONTO and CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter and fiscal year ended March 31, 2022. All dollar amounts in this press release are in United States dollars unless specified otherwise. Financial Highlights Delivered total revenue of $20.3 million in fiscal Q4 2022, an increase of 15% compared to fiscal Q4 2021 and, as expected, a decrease of 5% compared to fiscal Q3 2022 partly due to a large order in late fiscal Q3 2022 originally anticipated in fiscal Q4 2022. Generated total revenue of $76.7 million in fiscal year 2022, a decrease of 4% compared to fiscal...

Apollo partners with Hostplus to launch $1.25 billion Asia Pacific Credit Strategy

Written by Customer Service on June 22, 2022. Posted in Public Companies.

Multi-sector, yield-focused mandate leverages Apollo’s origination and credit expertise in APAC Region NEW YORK and MELBOURNE, Australia, June 22, 2022 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced the formation of an Asia Pacific Credit Strategy in strategic partnership with Hostplus, one of the five largest superannuation funds in Australia. The new strategy launches with US$1.25bn in assets, following an inaugural raise that includes a $500 million anchor commitment from Hostplus alongside Apollo’s internal and affiliated insurance balance sheets. The dedicated strategy brings Apollo’s global credit platform together with local expertise to capitalize on growing demand for private credit across Asia Pacific, providing companies and sponsors with flexible and bespoke solutions. The Asia Pacific Credit Strategy is designed...

Ashland completes sale of Section 1 Hercules Redevelopment Plan for land located in Sayreville, NJ to Parlin Section 1 Urban Renewal, LLC for $40 million

Written by Customer Service on June 22, 2022. Posted in Public Companies.

Ashland proceeds will fund environmental trust WILMINGTON, Del., June 22, 2022 (GLOBE NEWSWIRE) — Ashland Global Holdings Inc. (NYSE: ASH) today announced it has completed the sale of Section 1 of the Hercules Redevelopment Plan, approximately 77.8 acres of land located in Sayreville, NJ, to Parlin Section 1 Urban Renewal, LLC, an affiliate of Trammell Crow Company, in a transaction valued at $40 million with net proceeds estimated at $38.5 million. Previously, Ashland communicated that it would sell unutilized land to fund an environmental trust. “We are executing our plan to sell valuable land that is not being utilized by the company and placing the proceeds in an environmental trust,” said Guillermo Novo, chair and chief executive officer, Ashland. “Funding our environmental trust is a clear example of our environment, social...

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Day: June 22, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice